Sight Sciences (SGHT) EBITDA (2020 - 2026)

Sight Sciences' EBITDA history runs 7 years deep, the most recent figure standing at -$12.4 million for Q1 2026.

• On a quarterly basis, EBITDA rose 10.43% year-over-year to -$12.4 million in Q1 2026; TTM through Mar 2026 was -$35.7 million, a 28.22% increase from a year earlier, with the FY2025 full-year figure at -$37.1 million, up 26.58% from the prior year.
• EBITDA declined to -$12.4 million in Q1 2026 per SGHT's latest filing, from -$3.7 million in the prior quarter.
• Across five years, EBITDA topped out at -$3.7 million in Q4 2025 and bottomed at -$22.9 million in Q2 2022.
• The 5-year median for EBITDA is -$13.4 million (2023), against an average of -$14.2 million.
• Across the five-year window, EBITDA sank 106.43% in 2022 and soared 69.24% in 2025, its largest moves.
• Year by year, EBITDA stood at -$17.1 million in 2022, then soared by 34.85% to -$11.1 million in 2023, then dropped by 7.37% to -$11.9 million in 2024, then surged by 69.24% to -$3.7 million in 2025, then tumbled by 238.32% to -$12.4 million in 2026.
• Per Business Quant, the three latest SGHT EBITDA figures stand at -$12.4 million (Q1 2026), -$3.7 million (Q4 2025), and -$7.9 million (Q3 2025).